Opsy Holding

Opsy Holding EBITDA per Employee

The EBITDA per Employee of Opsy Holding (OPSYH.SL) as of Oct 29, 2026 is -2.45 M SEK. In the previous year, EBITDA per Employee was -1.38 M SEK — a change of 76.90% (lower).

EBITDA per Employee

-2.45 MSEK

YoY

76.90%

Last updated:

EBITDA per Employee of Opsy Holding is 2025 -2.45 M SEK. EBITDA per Employee of Opsy Holding was 2024 -1.38 M SEK. It decreases by 76.90% lower compared to the previous year.

The Opsy Holding EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-3.43 M SEK
Jan 1, 2019
-3.54 M SEK
Jan 1, 2020
-3.03 M SEK
Jan 1, 2021
-5.04 M SEK
Jan 1, 2022
-4.34 M SEK
Jan 1, 2023
-4.69 M SEK
Jan 1, 2024
-1.38 M SEK
Jan 1, 2025
-2.45 M SEK
The Opsy Holding EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-2.45 MSEK+76.90%
-1.38 MSEK-70.52%
-4.69 MSEK+8.08%
-4.34 MSEK-13.86%
-5.04 MSEK+66.05%
-3.03 MSEK-14.37%
-3.54 MSEK+3.39%
-3.43 MSEK-28.43%
-4.79 MSEK+68.49%
-2.84 MSEK+9.83%
-2.59 MSEK+177.04%
-933,714.29SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Opsy Holding Stock analysis

What does Opsy Holding do? Opsy Holding AB develops a software platform for insurance companies and medical advisors, focusing on anti-metastatic therapies related to the Wnt-5a protein. The company's products target the metastatic process through specific small molecules that interact with Wnt-5a mechanisms. Insurance companies and medical advisors purchase the platform to integrate advanced therapeutic insights into their services. The company's primary market segment consists of healthcare technology providers seeking innovative solutions for metastasis research. Opsy Holding AB's software platform is designed to support medical advisors and insurance firms in evaluating small molecules that specifically interact with the Wnt-5a protein's role in metastasis. The company's focus on Wnt-5a mechanisms positions its products for specialized healthcare applications. Insurance companies use the platform to enhance their risk assessment models with advanced therapeutic data. The company's business model centers on providing a technology platform that bridges medical research and insurance applications. By targeting the Wnt-5a protein's role in metastasis, Opsy Holding AB offers a niche solution for healthcare technology providers. The platform's value lies in its ability to connect specific small molecule evaluations with practical applications in insurance and medical advisory services. Opsy Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Opsy Holding stock

EBITDA per Employee of Opsy Holding is -2.45 M SEK in 2025.

EBITDA per Employee of Opsy Holding changed from -1.38 M SEK to -2.45 M SEK, representing a 76.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Opsy Holding since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Opsy Holding historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Opsy Holding

All Key Metrics — Opsy Holding